Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer(PRIAM) | recruiting | Phase 2 | 27 | The Netherlands Cancer InstituteOTHER | 2 | Dec 8, 2025 | clinicaltrials |
| NCT06676527 | Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma | recruiting | — | 39 | Jinling Hospital, ChinaOTHER | 1 | Dec 5, 2025 |
| clinicaltrials |
| NCT05768347 | Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC | active not recruiting | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07265414 | DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy | active not recruiting | — | 320 | Istituto Clinico HumanitasOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07261592 | Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 29 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257718 | The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial(FUTURE) | not yet recruiting | Phase 2 | 262 | Chiti ArturoOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05696444 | Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) | active not recruiting | N/A | 144 | Medtronic - MITGINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06537960 | Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers(TARDITEP) | recruiting | N/A | 66 | Hopital FochOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07037589 | Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?(BLUSH) | recruiting | — | 300 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07225205 | Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy | recruiting | N/A | 130 | Johns Hopkins UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT03837821 | (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer(CLONEVO) | active not recruiting | Early Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04428554 | Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy(BLAD-RAD01) | recruiting | Phase 2 | 130 | Institut Claudius RegaudOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05792722 | Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy | recruiting | N/A | 70 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06218433 | Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study) | recruiting | N/A | 200 | Tampere University HospitalOTHER | 2 | Nov 18, 2025 | clinicaltrials |
| NCT06525571 | Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection | recruiting | Phase 3 | 200 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer(GEMDOCE) | active not recruiting | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06190197 | Prophylactic Antibiotics in Cystectomy With Diversion | recruiting | Early Phase 1 | 120 | University of MinnesotaOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT02735252 | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer | active not recruiting | N/A | 156 | University of California, San FranciscoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02420847 | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | active not recruiting | Phase 1 / Phase 2 | 57 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07225374 | Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC | recruiting | Phase 2 | 48 | Samsung Medical CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04724018 | Sacituzumab Govitecan Plus EV in Metastatic UC | recruiting | Phase 1 / Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06396533 | Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)(INSITE) | recruiting | — | 92 | Fox Chase Cancer CenterOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT03022825 | QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 2 / Phase 3 | 190 | ImmunityBio, Inc.INDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06829823 | Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | not yet recruiting | Phase 2 | 20 | ImmunityBio, Inc.INDUSTRY | 0 | Oct 16, 2025 | clinicaltrials |
| NCT03978624 | Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | active not recruiting | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT06310759 | Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer(UROSCOUT-1) | recruiting | — | 3,000 | Tampere University HospitalOTHER | 4 | Oct 10, 2025 | clinicaltrials |
| NCT05649306 | Gender Related Coping and Survivorship for Genitourinary Cancers | recruiting | — | 80 | Johns Hopkins UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06427824 | Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy | recruiting | N/A | 85 | University of ChicagoOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05783271 | Validity of Parametric MRI Using VIRADS(metricMRI) | recruiting | N/A | 58 | Assiut UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07203989 | The Effect of Video Calls With Family Members During Operating Room Waiting on Stress, Anxiety, and Surgical Fear in Patients Undergoing Transurethral Resection of Bladder Tumor | not yet recruiting | N/A | 124 | Bitlis Eren UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204132 | Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy | recruiting | N/A | 180 | Changhai HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204301 | Enhancing Patient Comfort and Reducing Anxiety During Flexible Cystoscopy and Bladder Instillation in Bladder Cancer Patients: A Randomized Controlled Trial and Observational Study(Flexi-comfort) | not yet recruiting | N/A | 378 | Western University, CanadaOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT07204496 | A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer(γδ-T-BLADDER) | not yet recruiting | — | 20 | Shanghai 10th People's HospitalOTHER | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06727214 | Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer(AssiutU) | not yet recruiting | — | 87 | Sara Mahmoud Ahmed MahmoudOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04678362 | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma(TALASUR) | recruiting | Phase 2 | 50 | Centre Francois BaclesseOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07187063 | Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer | recruiting | N/A | 56 | Lahey ClinicOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07184021 | Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer(No Acronym) | not yet recruiting | Phase 2 | 30 | Assiut UniversityOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 8, 2025source: clinicaltrials